Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2012 2
2013 2
2015 1
2016 2
2017 1
2018 1
2019 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Motion analysis using 3D high-resolution frequency analysis.
Ueda T, Fujii K, Hirobayashi S, Yoshizawa T, Misawa T. Ueda T, et al. Among authors: yoshizawa t. IEEE Trans Image Process. 2013 Aug;22(8):2946-59. doi: 10.1109/TIP.2012.2228490. Epub 2012 Nov 20. IEEE Trans Image Process. 2013. PMID: 23192554
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G. Walter HS, et al. Among authors: yoshizawa t. Blood. 2016 Jan 28;127(4):411-9. doi: 10.1182/blood-2015-08-664086. Epub 2015 Nov 5. Blood. 2016. PMID: 26542378 Free PMC article. Clinical Trial.
Anti-tumor efficacy study of the Bruton's tyrosine kinase (BTK) inhibitor, ONO/GS-4059, in combination with the glycoengineered type II anti-CD20 monoclonal antibody obinutuzumab (GA101) demonstrates superior in vivo efficacy compared to ONO/GS-4059 in combination with rituximab.
Yasuhiro T, Sawada W, Klein C, Kozaki R, Hotta S, Yoshizawa T. Yasuhiro T, et al. Among authors: yoshizawa t. Leuk Lymphoma. 2017 Mar;58(3):699-707. doi: 10.1080/10428194.2016.1201567. Epub 2016 Aug 9. Leuk Lymphoma. 2017. PMID: 27684575